Brilacidin has the potential to mimimize the burden of antimicrobial resistance, relative to approved ABSSSI compounds, and its anti-inflammatory activity may promote the clinical resolution or healing of skin lesions.
"its anti-inflammatory”, is this a hint that the Brilacidin-OM trial currently underway is already alluding to the fact that Brilacidin does in fact provide anti-inflammatory support?
When mathematics and data are used in prediction we call this an 'educated guess'.
So, for those that might think I am daydreaming at $800 CTIX, please at least agree to call it 'educated daydreaming'.